Santhera Pharmaceuticals was formed by the merger of Graffinity Pharmaceuticals AG and MyoContract. Santhera is focused on the discovery, development of small molecules for treating severe neuromuscular diseases. Santhera’s lead discovery programs are based on Graffinity’s RAISE process, and Santhera still has access to this proprietary platform. The company’s lead products are Idebenone (SNT-MC17) and Fipamezole (JP-1730).